Optimal control of blood glucose: The diabetic patient or the machine?

Science Translational Medicine

Volumn 2, Issue 27, 2010, Pages

  Brown, Larry ^a   Edelman, Elazer R ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; SOMATOSTATIN; GLUCOSE BLOOD LEVEL;

ALLOTRANSPLANTATION; BLOOD GLUCOSE MONITORING; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIET THERAPY; DRUG RESPONSE; EXERCISE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFUSION PUMP; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; ANALYSIS; ARTIFICIAL PANCREAS; BLOOD; DIABETES MELLITUS, TYPE 1; METABOLISM;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; GLUCAGON; HUMANS; INSULIN; PANCREAS, ARTIFICIAL;

EID: 77952985211     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001083     Document Type: Review

References (50)

1. E. P. Joslin, The treatment of diabetes with diet and exercise. Diabetic Manual for the Mutual Use of Doctor and Patient (Lea & Febiger, Philadelphia, PA, ed. 5, 1933), pp. 100-120.
2. E. P. Joslin, A Diabetic Manual for the Mutual Use of Doctor and Patient (Lea & Febinger, Philadelphia, PA, ed. 1, 1918).
3. P. E. Cryer, J. E. Gerich, Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus. N. Engl. J. Med. 313, 232-241 (1985).
4. The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977-986 (1993).
5. A. J. Palmer, S. Roze, W. J. Valentine, M. E. Minshall, M. Lammert, L. Nicklasson, G. A. Spinas, Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: Increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Curr. Med. Res. Opin. 20 (suppl. 1), S67-S73 (2004).
6. J. Q. Purnell, J. E. Hokanson, S. M. Marcovina, M. W. Steffes, P. A. Cleary, J. D. Brunzell, Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. Diabetes Control and Complications Trial. JAMA 280, 140-146 (1998).
7. O. P. McGuinness, S. R. Myers, D. Neal, A. D. Cherrington, Chronic hyperinsulinemia decreases insulin action but not insulin sensitivity. Metabolism 39, 931-937 (1990).
8. F. H. El-Khatib, S. J. Russell, D. M. Nathan, R. G. Sutherlin, E. D. R. Damiano, A Bi-hormonal closed-loop artificial pancreas for Type 1 diabetes. Sci. Transl. Med. 2, 27ra27 (2010).
9. P. Langerhans, Beiträge zur mikroskopischen Anatomie der Bauchspeicheldruse, Doctoral thesis [Berlin Pathological Institute (1869)], reprinted in English in Bull. Inst. Hist. Med. 5, 259-297 (1933).
10. E. L. Opie, On the histology of the islands of Langerhans of the pancreas. BJHH 11, 205-209 (1900).
11. O. Cabrera, D. M. Berman, N. S. Kenyon, C. Ricordi, P.-O. Berggren, A. Caicedo, The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc. Natl. Acad. Sci. U. S. A. 103, 2334-2339 (2006).
12. J. P. Thaler, D. E. Cummings, Metabolism: Food alert. Nature 452, 941-942 (2008).
13. C. Kimball, J. Murlin, Aqueous extracts of pancreas III. Some precipitation reactions of insulin. J. Biol. Chem. 58, 337-348 (1923).
14. K. S. Polonsky, B. D. Given, E. Van Cauter, Twenty-fourhour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J. Clin. Invest. 81, 442-448 (1988).
15. E. A. Doyle, S. A. Weinzimer, A. T. Steffen, J. A. Ahern, M. Vincent, W. V. Tamborlane, A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 27, 1554-1558 (2004).
16. J. A. H. Ahern, E. A. Boland, R. Doane, J. J. Ahern, P. Rose, M. Vincent, W. V. Tamborlane, Insulin pump therapy in pediatrics: A therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr. Diabetes 3, 10-15 (2002).
17. H. Hanaire-Broutin, V. Melki, S. Bessieres-Lacombe, J.-P. Tauber, The Study Group for the Development of Pump Therapy in Diabetes, Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: A randomized study. Diabetes Care 23, 1232-1235 (2000).
18. E. Renard, Intensive insulin therapy today: 'Basal-bolus' using multiple daily injections or CSII? Diabetes Metab. 31, 4S40-4S44 (2005).
19. J. Bondia, E. Dassau, H. Zisser, R. Calm, J. Vehí, L. Jovanovǐ, F. J. Doyle, III, Coordinated basal-bolus infusion for tighter postprandial glucose control in insulin pump therapy. J. Diabetes Sci. Tech. 3, 89-97 (2009).
20. E. J. Fogt, L. M. Dodd, E. M. Jenning, A. H. Clemens, Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system (Biostator). Clin. Chem. 24, 1366-1372 (1978).
21. R. Hovorka, Continuous glucose monitoring and closed-loop systems. Diabet. Med. 23, 1-12 (2006).
22. R. Hovorka, J. M. Allen, D. Elleri, L. J. Chassin, J. Harris, D. Xing, C. Kollman, T. Hovorka, A. M. F. Larsen, M. Nodale, A. De Palma, M. E. Wilinska, C. L. Acerini, D. B. Dunger, Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: A phase 2 randomised crossover trial. Lancet 375, 743-751 (2010).
23. K. Rebrin, G. M. Steil, W. P. V. Antwerp, J. J. Mastrototaro, Subcutaneous glucose predicts plasma glucose independent of insulin: Implications for continuous monitoring. Am. J. Physiol. Endocrinol. Metab. 277, E561-E571 (1999).
24. G. Steil, K. Rebrin, J. J. Mastrototaro, Metabolic modelling and the closed-loop insulin delivery problem. Diabetes Res. Clin. Pract. 74 (suppl. 2), S183-S186 (2006).
25. S. A. Weinzimer, G. M. Steil, K. L. Swan, J. Dziura, N. Kurtz, W. V. Tamborlane, Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31, 934-939 (2008).
26. R. Ratner, F. Whitehouse, M. S. Fineman, S. Strobel, L. Shen, D. G. Maggs, O. G. Kolterman, C. Weyer, Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets. Exp. Clin. Endocrinol. Diabetes 113, 199-204 (2005).
27. C. Weyer, A. Gottlieb, D. D. Kim, K. Lutz, S. Schwartz, M. Gutierrez, Y. Wang, J. A. Ruggles, O. G. Kolterman, D. G. Maggs, Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: A dose-timing study. Diabetes Care 26, 3074-3079 (2003).
28. D. Bruttomesso, C. Fongher, B. Silvestri, S. Barberio, M. C. Marescotti, E. Iori, A. Valerio, D. Crazzolara, A. Pianta, A. Tiengo, S. Del Prato, Combination of continuous subcutaneous infusion of insulin and octreotide in Type 1 diabetic patients. Diabetes Res. Clin. Pract. 51, 97-105 (2001).
29. M. Bosnak, B. Dikici, O. Dogru, M. Davutoglu, K. Haspolat, Somatostatin therapy in the management of resistant diabetic ketoacidosis. Diabetes Care 25, 629-630 (2002).
30. E. R. Edelman, L. Brown, R. Langer, Quantification of insulin release from implantable polymer-based delivery systems and augmentation of therapeutic effect with simultaneous release of somatostatin. J. Pharm. Sci. 85, 1271-1275 (1996).
31. A. D. Cherrington, Central versus peripheral glucose sensing and the response to hypoglycemia. Diabetes 57, 1158-1159 (2008).
32. Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isami, S. Motoyoshi, Y. Kojima, N. Furuyoshi, M. Shichiri, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28, 103-117 (1995).
33. G. B. Bolli, I. S. Gottesman, P. E. Cryer, J. E. Gerich, Glucose counterregulation during prolonged hypoglycemia in normal humans. Am. J. Physiol. 247, E206-E214 (1984).
34. Y. T. Kruszynska, P. D. Home, K. G. M. M. Alberti, Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats. Diabetologia 28, 167-171 (1985).
35. L. Matilainen, K. L. Larsen, R. Wimmer, P. Keski-Rahkonen, S. Auriola, T. Järvinen, P. Jarho, The effect of cyclodextrins on chemical and physical stability of glucagon and characterization of glucagon/γ-CD inclusion complexes. J. Pharm. Sci. 97, 2720-2729 (2008).
36. S. Onoue, S. Iwasa, T. Kojima, F. Katoh, K. Debari, K. Koh, Y. Matsuda, T. Yajima, Structural transition of glucagon in the concentrated solution observed by electrophoretic and spectroscopic techniques. J. Chromatogr. A 1109, 167-173 (2006).
37. J. S. Pedersen, D. Dikov, J. L. Flink, H. A. Hjuler, G. Christiansen, D. E. Otzen, The changing face of glucagon fi-brillation: Structural polymorphism and conformational imprinting. J. Mol. Biol. 355, 501-523 (2006).
38. S. Frokjaer, D. E. Otzen, Protein drug stability: A formulation challenge. Nat. Rev. Drug Discov. 4, 298-306 (2005).
39. J. Beck, R. Angus, B. Madsen, D. Britt, B. Vernon, K. T. Nguyen, Islet encapsulation: Strategies to enhance islet cell functions. Tissue Eng. 13, 589-599 (2007).
40. M. D. Bellin, R. Kandaswamy, J. Parkey, H. J. Zhang, B. Liu, S. H. Ihm, J. D. Ansite, J. Witson, P. Bansal-Pakala, A. N. Balamurugan, K. Papas, D. E. R. Sutherland, A. Moran, B. J. Hering, Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am. J. Transplant. 8, 2463-2470 (2008).
41. B. Gimi, J. Kwon, A. Kuznetsov, B. Vachha, R. L. Magin, L. H. Philipson, J.-B. Lee, A. Nanoporous, Transparent microcontainer for encapsulated islet therapy. J. Diabetes Sci. Tech. 3, 297-303 (2009).
42. R. P. Lanza, J. L. Hayes, W. L. Chick, Encapsulated cell technology. Nat. Biotechnol. 14, 1107-1111 (1996).
43. E. A. Ryan, B. W. Paty, P. A. Senior, D. Bigam, E. Alfadhli, N. M. Kneteman, J. R. T. Lakey, A. M. J. Shapiro, Five-year follow-up after clinical islet transplantation. Diabetes 54, 2060-2069 (2005). (Pubitemid 40911269)
44. P. G. Stock, J. A. Bluestone, Beta-cell replacement for type I diabetes. Annu. Rev. Med. 55, 133-156 (2004).
45. F. M. Gribble, Metabolism: A higher power for insulin. Nature 434, 965-966 (2005).
46. L. J. Goodyear, B. B. Kahn, Exercise, glucose transport, and insulin sensitivity. Annu. Rev. Med. 49, 235-261 (1998).
47. A. Thorell, M. F. Hirshman, J. Nygren, L. Jorfeldt, J. F. P. Wojtaszewski, S. D. Dufresne, E. S. Horton, O. Ljungqvist, L. J. Goodyear, Exercise and insulin cause GLUT-4 translocation in human skeletal muscle. Am. J. Physiol. 277, E733-E741 (1999).
48. P. H. Andersen, S. Lund, O. Schmitz, S. Junker, B. B. Kahn, O. Pedersen, Increased insulin-stimulated glucose uptake in athletes: The importance of GLUT4 mRNA, GLUT4 protein and fibre type composition of skeletal muscle. Acta Physiol. Scand. 149, 393-404 (1993).
49. J. R. Daugaard, E. A. Richter, Relationship between muscle fibre composition, glucose transporter protein 4 and exercise training: Possible consequences in non-insulindependent diabetes mellitus. Acta Physiol. Scand. 171, 267-276 (2001).
50. J. Steinberger, S. R. Daniels, American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young), American Heart Association Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism), Obesity, insulin resistance, diabetes, and cardiovascular risk in children. Circulation 107, 1448-1453 (2003).